Recently, 2024 American Society of Clinical Oncology (ASCO) reported the long-term follow-up result of phase 3, randomized, open-label CROWN study achieving an amazing over 60 months median PFS, which aimed to evaluate lorlatinib in treatment-naïve patients with advanced ALK-positive NSCLC (19). This evidence concerns the gene ALK and non-small cell lung carcinoma.